We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioSolveIT and Optibrium Sign Collaboration Agreement
News

BioSolveIT and Optibrium Sign Collaboration Agreement

BioSolveIT and Optibrium Sign Collaboration Agreement
News

BioSolveIT and Optibrium Sign Collaboration Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioSolveIT and Optibrium Sign Collaboration Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Optibrium™ and BioSolveIT have announced that they will collaborate to create seamlessly integrated data analysis, visualization and simulation software for drug research.

The two companies are known for their best-in-class prediction tools for selection and optimization of potential therapeutics, where it is essential to recognize and resolve potential problems as early as possible. Computer software for ‘virtual design’ of drug candidate molecules prior to synthesis and testing is ubiquitous in medicinal chemistry and an important time-saver in research.

As part of the agreement, both companies will exchange their proprietary technologies; the first phase will incorporate a suite of high-quality predictive models of absorption, distribution, metabolism and excretion (ADME) and physicochemical properties from Optibrium's StarDrop™ platform as an optional feature within BioSolveIT's SeeSAR™ package. This will be followed by the integration of SeeSAR's capabilities to work with 3D structural information into StarDrop's unique environment that guides the design of high quality compounds.

Dr. Matt Segall, CEO of Optibrium, commented: “Our customers tell us that they want to understand the relationship between the SAR in their data and the 3D structures of their compounds and protein targets. BioSolveIT's state-of-the-art and scientifically rigorous approach is unparalleled when it comes to visualizing and predicting 3D binding - it was an obvious first choice to work with them. There is great synergy between our platforms' capabilities that needs seamless integration to provide the most value. The strongest binding molecule is of no use if it doesn't achieve sufficient exposure in a patient. Therefore, the discovery of a new drug is a multi-faceted optimization challenge. The adsorption, distribution, metabolism, and excretion (ADME) behaviour, as well as the toxicity of compounds need to be always at the forefront of drug discovery - alongside target inhibition.”

BioSolveIT's Director of Application Science, Dr. Marcus Gastreich, said: “Having an integrated solution for the researcher is like a head-up display: The impact of easy-to-use software accompanying the research process must be non-obstructive but always there: All parameters nicely organized, plus a powerful and minimalistic alerting system are the keys to avoid costly failure.”

Dr. Christian Lemmen, CEO of BioSolveIT, said: “Both companies share a passion for intuitive and clean user interfaces - an aspect which is widely neglected in scientific software. Management has realized that users need easily accessible functionality besides scientific value in software. For both, we are proud to have Optibrium as a like-minded partner, their ADME property predictions are highly regarded by the industry.”

Advertisement